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Introduction: Although effective live attenuated yellow fever (YF) vaccines have been
available for over 9 decades sporadic outbreaks continue to occur in endemic regions.
These may be linked to several factors including epidemiological factors such as vector
and intermediate host distribution or vaccine coverage and efficacy. The World Health
Organization’s research priorities include gathering systematic evidence around the
potential need for booster vaccination with YF vaccine whether this follows full or
fractional doses in children. Knowledge on the longevity of response to YF vaccine
and the implications of this response needs to be consolidated to guide future
vaccination policy.
Methods: We measured anti-YF IgG by microneutralization assay in a group of 481
African infants who had received YF vaccine as part of routine EPI programmes, to
explore serological protection from YF 5–6 years post YF vaccination, as well as the
effect of co variates.
Findings: Notably, 22.2% of the cohort had undetectable antibody concentrations, with
another 7.5% revealing concentrations below the threshold of seropositivity of 0.5 IU/mL.
Sex, season, country and time since vaccination did not affect the longevity of antibody
concentration or having antibody concentrations above a defined threshold.
Conclusion:Roughly 30% of children in this cohort did not demonstrate anti-yellow fever
antibody concentrations above the defined threshold of protection, with 20% having no
demonstrable antibody. Knowledge on the longevity of response to YF vaccine and the
implications needs to be consolidated to guide future vaccination policy.
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BACKGROUND
Effective vaccines against yellow fever (YF) virus have been
available for over nine decades (1). In endemic regions of the
world, these vaccines are generally used as part of the routine
Expanded Programme on Immunization (EPI) vaccines given
to children in infancy (2). The currently available YF vaccines
are live attenuated vaccines shown to be highly immunogenic
and to provide long term protection after a single dose (1).The
primary correlate of protection is neutralizing antibody, though
cell mediated and innate immune responses have also been
proposed to play a role (3).
In 2014 the World Health Organization (WHO) changed
its recommendation of 10-yearly vaccination against YF to a
single dose for life. Fractional doses are also in use during
epidemics when vaccine supplies are limited. However, WHO
has recognized the need for studies that establish the longevity of
response to a single YF vaccine dose as a priority, particularly in
special groups such as infants, immunocompromised individuals
and those who received fractional doses of the vaccine (4–6).
Establishing the longevity of response following single dose YF
vaccination is key to guide future policy on the use of the
vaccine, particularly in endemic settings. If the longevity of
response is found to be sub optimal in these groups, millions
may be vulnerable to infection in these endemic areas. The
current projections of population coverage under the 2017–2026
Eliminating YF Epidemics (EYE) strategy, which implements YF
vaccination in infants as part of the EPI in endemic countries (7),
could be off-target if serological and possibly clinical protection
from disease is short-lived.
The proportion of individuals with protective anti-yellow
fever antibody reported in the literature ranges from 69 to 98% up
to 11 years post vaccination (8–12). Data from children remains
limited but are of particular importance, given that in endemic
settings a single dose for life given in infancy would be the
only YF vaccine administration. It is also possible that immune
responses to YF differ between adults and children and data from
children showing both production and longevity of protective
antibody need to be generated, especially since it has already
been demonstrated that infants show poorer and sometimes
varied seroconversion rates following YF vaccination (13–16) in
different settings. This finding is likely to impact on the longevity
of antibody response.
To our knowledge there are limited data on longevity of YF
antibody available from the African continent. One previous
study by Domingo et al. involving children from Ghana and
Mali examined longevity of antibody response to YF vaccine in
African infants who had received the vaccines according to EPI
schedules but as part of large randomized controlled trials (ideal
settings). In these circumstances, “real life” factors such as cold
chain maintenance and other programmatic limitations are less
likely to affect overall outcome given the influence of full time
study teams (17). Generating data on the antibody concentrations
to YF several years post vaccination under routine EPI program
conditions therefore remains important to inform the WHO
guidelines with a view to assess need for booster doses if the only
dose of YF vaccine is administered in infancy.
We measured anti-YF IgG by microneutralization assay in a
group of African infants who had received YF vaccine as part of
routine EPI programmes, to explore serological protection from
YF 5–6 years post YF vaccination.
We also explored the impact of cofactors such as sex, season
of vaccination, country and time since vaccination on the
concentration of anti-YF IgG neutralizing antibodies.
ROLE OF FUNDING SOURCE
The funders had no role in the study design, data collection, data
analysis, data interpretation, or manuscript write up.
ETHICAL APPROVALS
Written informed consent according Good Clinical Practice
guidelines and the Declaration of Helsinki was obtained from a
parent of each participant. The initial and current studies were
approved by the ethics committees at the host institutions and
Programme for Appropriate Technology in Health (PATH).
METHODS
Population and Samples
We assayed YF antibody responses in a cohort of African children
from The Gambia (N = 243) and Mali (N = 238) using banked
serum samples which were originally collected as part of an
antibody persistence study to assess persistence of antibodies to
MenAfriVac 4–5 years after the children had originally received
MenAfriVac at 12–23 months of age. With these 481 samples
we would have a power of 1.0 to detect a 10% difference in
the proportion of individuals attaining protective titres assuming
that one vaccine dose would result in 98% of children having
protective anti-YF antibody titres 5–6 years post vaccination at
a 5% alpha.
These blood samples were collected between October 2011
and April 2012 and included samples from all children who
could be traced 4–5 years post MenAfriVac vaccination. Left over
banked serum was accessed for this analysis (18) and current
assays were conducted between January and March 2019.
Records of YF Vaccination
As a prerequisite to enrolment into the MenAfrivac trial at age
12–23 months, the infants were required to have documentation
showing that they received all recommended vaccinations for
age which included one dose of YF vaccine received up to 1-
year pre enrolment. The EPI program in Mali utilized yellow
fever vaccines from Institute Pasteur, SANOFI Pasteur and
BIOMANGUINHOS. The Gambia EPI utilized vaccines from
vaccines from Institute Pasteur only. All blood samples assayed
in this study were collected between 5- and 6-years post YF
vaccination (corresponding to 4–5 years post study enrolment)
and remaining aliquots had been stored at −70◦C at the
University of Siena Sera Bank in Italy. Samples were maintained
at this temperature while stored at and during transport form the
clinical sites and during transport to the assay lab.
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Lab Assays
The concentrations of neutralizing antibodies to YF virus
were tested at the Robert Koch Institute in Berlin using a
microneutralization assay (17). Briefly, 100 TCDI50 infectious
doses of a YF virus 17-D (Stamaril, Sanofi Pasteur, Val de Reuil,
France) were incubated with serial 2-fold dilutions of sera before
inoculation into Vero cells cultured in 96-well plates. The cells
were then microscopically examined for cytopathic effect 7 days
later. Reference serum samples were run with each plate to
minimize batch effects and ensure suitability of assay.
Cut Offs
Although neutralizing titres of ≥1:5 or 1:10 (17, 19) are
considered a surrogate of protection (seroprotection), difference
in in assay methods may limit comparability of results from
different laboratories. The titres were thus standardized by
conversion into antibody concentrations in IU/mL using aWHO
international standard (WHO International Standard, NISBC
99/616 reconstituted at 143 IU/ml) to allow for comparability
with other available data. This was done by comparison with
two positive controls for yellow fever neutralizing antibodies
included with every assay. These controls were calibrated at
426.82 and 106.7 IU/ml, respectively. Based on earlier studies
(20–22), we applied a concentration threshold of ≥0·5 IU/ml to
discriminate seropositivity.
Data Analysis
Where applicable, antibody concentrations were normalized
by log 2 transformation. Uni- and multivariable mixed effects
models were applied, adjusting for sex, season of vaccination
and time since vaccination. Separate models were run for
seropositivity (binary outcome) and raw post-vaccination
antibody titres (continuous). Means, median, proportions and
odds ratios were calculated along with their corresponding 95%
confidence intervals. An alpha error level of 5% was used to judge
significance. All analyses were performed using Stata version
14·2 (23).
RESULTS
Sera from 481 children (238 from Mali and 243 from The
Gambia) were available of which 224 were male and 256 were
female. Sex was missing for one participant.
Participants Demonstrating Seropositivity
5–6 Years Post Vaccination
The median antibody concentration was 1.2 [interquartile range
(0.4–2.4)]. Notably, 22.2% of the cohort had undetectable
antibody concentrations, with another 7.5% revealing
concentrations below the threshold of seropositivity of 0.5
IU/mL. Table 1 summarizes antibody concentrations by country.
The antibody concentrations did not differ significantly by
country (p = 0.13) with a trend to higher concentrations in the
Malian cohort.
TABLE 1 | Anti-YF antibody concentrations (UI/mL).
Mean (95% CI) Percentage with
undetectable antibody
(% 95% CI)
Percentage with
antibody below
protective
threshold (%
95% CI)
Overall (N = 481) 2.9 (2.3–3.5) 22.2 (18.6–26.2) 29.7 (25.7–34.0)
Mali (N =238) 3.4 (2.3–4.4) 25.6 (20.2–31.7) 31.5 (25.7–37.8)
Gambia (N = 243) 2.5 (1.9–3.0) 18.9 (14.2–24.4) 28.0 (22.4–34.1)
95% CI, 95% confidence interval; IQR, interquartile range; YF Ab, YF antibody; N, number
of observations; NB, Percentage with concentrations below the protective threshold
includes individuals with undetectable concentrations.
Participants With Defined Protective
Antibody Titer
The median antibody titer was 1:12.0 [interquartile range (1:4.0–
1:22.0)]. Of the cohort, 21.8% had undetectable antibody titres at
this time point, with another 5% revealing concentrations below
the defined titer for protection of 1:5.
Distribution of Antibody Concentrations
Antibody concentration distribution was non- significantly
higher concentrations in Mali (t = 1.51; p = 0.13) and showing
generally low antibody tires 5–6 years post vaccination following
a single dose of YF vaccine (Supplementary Figure 1).
Effect of Covariates on Antibody
Concentration
Sex, season, country and time since vaccination did not affect
the longevity of antibody concentration in uni- or multivariable
regression models for antibody concentration as a continuous
variable (Table 2).
The odds of maintaining an antibody concentration above
0.5 UI/mL was also unaffected by the sex, season of vaccination,
country or time since vaccination (Table 3).
Similar findings were noted when the cut off for titres of ≥1:5
or 1:10 was applied.
DISCUSSION
The analysis of serum samples from 481 children vaccinated
with one dose of YF vaccine in infancy showed that roughly
30% did not have protective antibody concentrations of 0.5
UI/ml (17) 5–6 years after vaccination. Most of this group had
undetectable antibody concentrations (seronegative) and even
where detectable, concentrations were below 0.1 IU/mL. This
finding is concerning and may have significant implications for
long term protection from YF in individuals who have received
the YF vaccine as a single dose in the first year of life within EPI
programs and in line with the current WHO recommendations.
By comparison, a small study in adults from the Netherlands
who had received a fractional dose of YF vaccine demonstrated
that 98% of the individuals vaccinated were still protected 10
years later (10), but the sample size of 40 individuals was small
and represented only 48% of the original recipients of the vaccine
(10). A more recent report followed up 349 Chinese adults
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TABLE 2 | Association of covariates at time of vaccination with log2 anti-YF antibody concentrations.
Univariable (crude) Multivariable (adjusted)
Covariate N Coef. (95% CI) p-value Coef. (95% CI) p-value
Sex
Male* 256 0.00 - - – 0.00 - - –
Female 224 0.02 (−0.15 to 0.20) 0.7767 0.03 (−0.15 to 0.20) 0.7590
Season
Dry* 311 0.00 - - – 1.00 - - –
Rainy 170 0.02 (−0.16 to 0.20) 0.8479 0.02 (−0.16 to 0.20) 0.8239
Country
Mali* 232 0.00 - - – 0.00 - - –
Gambia 179 −0.04 (−0.21 to 0.13) 0.6343 −0.04 (−0.21 to 0.13) 0.6270
Time since vaccination – 0.07 (−0.19 to 0.34) 0.5798 0.08 (−0.18 to 0.34) 0.5656
NB, Sex missing for 1 participant. *Reference stratum. N, number of observations; Coef, coeficient; 95% CI, 95% confidence interval. Results of separate uni- and multi-variable
linear regression. Multi-variable model adjusted for, sex and season of vaccination and time since vaccination.
TABLE 3 | Association of covariates at time of vaccination with recording a threshold of anti-YF antibody concentrations of 0.5 or more.
Univariable (crude) Multivariable (adjusted)
Covariate N Mean OR (95% CI) p-value OR (95% CI) p-value
Sex
Male* 256 2.8 1.00 - - – 1.00 - - –
Female 224 3.0 1.12 (076–1.66) 0.5632 1.12 (0.75–1.65) 0.5846
Season
Dry* 311 3.0 1.00 - - – 1.00 - - –
Rainy 170 2.8 0.21 (0.66–1.51) 0.9992 1.02 (0.68–1.54) 0.9102
Country
Mali* 232 3.4 1.00 - - – 1.00 - - –
Gambia 179 2.5 1.20 (0.81–1.77) 0.3708 1.20 (0.81–1.77) 0.3652
Time since – – 1.05 (0.57–1.91) 0.8853 1.06 (0.58–1.92) 0.8510
vaccination
NB, Sex missing for 1 participant. *Reference stratum. N, number of observations; Coef, coeficient; 95% CI, 95% confidence interval. Results of separate uni- and multi-variable
logistic regression. Multi-variable model adjusted for, sex and season of vaccination and time since vaccination.
who had received YF vaccine prior to deployment to Africa
and reported negligible concentrations 11 years post vaccination
(12). Several other studies have demonstrated similar decline in
antibody in adults at varied time points post vaccination (9, 11,
24–26). The findings following a fractional dose of YF vaccine
in The Netherlands differ from ours with a larger proportion
retaining protective concentration but are in keeping with other
reports of declining antibody from adults. All of these data
are generated from studies in adults, unlike the pediatric data
presented here. In addition, the different geographical settings
(Europe, Asia vs. YF endemic Africa) have no or different prior
exposure and other environmental differences which could also
play a role in acquisition and persistence of antibody. Natural
exposure differs between non-endemic and endemic settings and
potentially also between age groups.
Following a full dose of YF vaccine in US adults all individuals
who received multiple doses of YF vaccine had protective
concentrations, irrespective of the time since vaccination. When
only one dose had been received however, 94% had protective
concentrations if that dose was <10 years from testing. When
tested 10 or more years later however, only 82% had protective
concentrations (11). These findings would suggest that even
in adults, booster vaccinations may be warranted in certain
populations. This view was published in a recent opinion
piece (8).
Only 69% of children in Brazil maintained protective
concentrations 10 years after receiving a full vaccine dose (8,
9). To our knowledge there has only been one study on the
African continent assessing antibody longevity in children. This
recent study assessed longevity in children who had received YF
vaccine as part of 2 randomized controlled clinical trials. The
study similarly demonstrated a drastic decline of YF immunity
in children vaccinated as infants even within the ideal clinical
trial settings with 50.4% (4.5 years post vaccination) and 43.1%
(6 years post vaccination) retaining seropositivity in Mali and
Ghana, respectively (17). These findings may be compounded by
several factors including natural disease exposure but in keeping
with ours suggest a population of children vulnerable to YF
infection several years post vaccination irrespective of setting
where vaccine was received.
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Given the limited data available on persistence of antibody
to YF in children and previous similar findings, our findings
are timely and have the potential to inform future discussions
regarding policy for YF vaccine use. The data from Brazil
however does not state the vaccine used and this information
may be an important consideration for the longevity of vaccine
response. Our cohorts received similar vaccines although we do
not have data per individual for vaccines received.
The sex, season of vaccination and time since vaccination
did not impact the longevity of anti-YF antibody concentration
5–6 years post vaccination. This is similar to findings from a
US cohort of adult travelers 3–4 years post vaccination with
YF vaccine prior to travel to endemic regions. The only factors
associated with higher antibody concentrations 3–4 years post
vaccination were early onset of detection and higher antibody
concentration 1-month post vaccination (27). These were not
variables available for our analysis. In African studies sex was also
not found to contribute to seropositivity (17).
LIMITATIONS
The precise age at vaccination of our cohort (no date of
birth records available) and anthropometric measures at time
of vaccination were unknown and could have impact on the
longevity of antibody. There may also be limitations within the
EPI system ranging from cold chain maintenance to vaccine
delivery methods that could have affected our results. Given the
similarity of our findings with those from children vaccinated in
ideal clinical trial settings however (17), this is unlikely.
CONCLUSION
As identified by WHO there is a need to gather evidence around
the potential need for booster vaccination with YF vaccine
whether this follows full or fractional doses in children and
adults (4, 5, 28). This knowledge needs to be consolidated
to guide future vaccination policy. Our findings suggest that
children in this region of sub-Saharan Africa may require booster
doses due at least by school entry age. Additional studies that
explore antibody functionality and not just quantity would also
be warranted as the function and not just the quantity of antibody
is likely to mediate protection.
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